MTOR and papillary adenocarcinoma: We similarly analysed the spatial co-activation of the MAPK and mTOR pathways in AKTnegative/MAPKmedium-high papillary adenocarcinoma (PAC) tumours, which showed that PACs either classified as ‘MAPK/mTOR’ (PAC_OL; pERK/p4EBP1 > 15%) or as ‘Null’ signature tumours, again indicating inter-tumour signalling heterogeneity within this histopathology group (Supplementary Fig. S2b,c).